Avid Bioservices Inc (CDMO)

[pphmtoolong]

Given the clinical data to date, I know Bavi is a much safer medication than our benchmark Avastin, and I strongly suspect Bavi is at least as effective in several major solid tumor types. Based on the maturing second line NSCLC MOS data, I also believe Bavi is more likely than not approvable. If this is correct and based on what Steve King recently said, I further believe Peregrine will find a significant partner or buyer in the next few months.

Given the above what might Peregrine be worth to a significant buyer? I don't know the number, but I do know it's a lot more the $3 a share. So, let's see how low this "pause" takes us, and those who share the above assessment know what to do.

Paul